TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06371222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: 5 mg for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker
Description: controlled group
Study: NCT06185582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: 25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: 25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
Study: NCT05157100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingrezza Pill
Description: Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.
Study: NCT05519514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortiment
Description: Budesonide 9 mg prolonged release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Experimental (Budesonide 9 mg prolonged release tablets)
Study: NCT06312735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR (Reducept)
Description: Reducept is a novel VR intervention that consists of a combination of pain neuroscience education (PNE) and pain management techniques. It includes different psychological therapy modalities (e.g. acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT) and hypnotherapy) into a single application.
Study: NCT05810363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate - propofol mixture
Description: Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
Study: NCT05770037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT05842759

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Monitoring
Description: Continuous blood pressure monitoring

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Norepinephrine preparation
Description: Norepinephrine infusion will be prepared and connected to peripheral or central venous catheter (infusion will not be started)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Propofol administration
Description: Propofol infusion will be started only when clinical effects of opioid are noticeable: 1.5 mg/kg propofol in patients less than 55 years old and 1.0 mg/kg propofol in patients 55 years or older over 90 seconds

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Alarm adjustment
Description: Lower mean arterial pressure alarm threshold will be set to 75 mmHg

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intervention threshold
Description: Lower mean arterial pressure intervention threshold will be 75 mmHg: continuous norepinephrine infusion will be started when mean arterial blood decreases below 75 mmHg
Study: NCT04637815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Network Intervention
Description: Every 2 weeks, residents attend meetings with their case manager. These meetings are customized to the needs of the resident at the time of the meeting. Participants randomized into the Motivational Network Intervention arm are offered an additional discussion about their social networks. Case managers ask participants to answer a series of standardized questions about people they know. After these questions are answered, case managers show participants a series of images representing these answers. While showing these images, case mangers engage the participant in discussions about what they notice using Motivational Interviewing techniques. The goal is to discuss what the participant wants to change and state strategies about achieving these changes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Residents attend regular case management meetings with their case managers as a condition of their residency in the housing program. These sessions are customized do the needs of the resident at the time of the meeting. Participants randomized into the usual care arm will be offered these sessions every 2 weeks.
Study: NCT06264076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A novel instrument for ligament balancing in total knee arthroplasty
Description: Patients will be evaluated perioperatively for ligament balance. When indicated, the novel instrument will guide puncturing of the medial collateral ligament in a systematic and step-wise fashion. Achieved ligament balance will be observed and controlled by computer navigation and a ligament tensor.
Study: NCT04928599

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records

Intervention type: OTHER
Intervention: Interview
Description: Complete interview
Study: NCT05921435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341, D958
Description: A single dose of 1tablet under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341, D958
Description: A single dose of 1tablet under fasting condition
Study: NCT05876507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise
Description: Progressive relaxation exercises will take 25-30 minutes of patients daily.
Study: NCT04928599

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT04683029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab Dose 1 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Guselkumab Dose 2 will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously or subcutaneously.
Study: NCT05768412

Intervention type: PROCEDURE
Intervention: Radial Artery Access
Description: The radial artery is stabilized between the thumb and forefinger of the left hand and 1 to 2 mL of subcutaneous lidocaine is used to create a wheal over the zone of planned entry.
Study: NCT04467086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Propranolol enterally at a starting dose of 20mg every 6h for 2-4 doses, and then re-assessed for upwards titration every 24 hours (+/- 6 hours) at 10mg dose increases depending on clinical response. Maximum dose of 60mg every 6h. Titration decision to be made by clinical team at daily rounds.~Daily titration will be guided by hemodynamic markers indicative of the expected sympatholysis from propranolol. Upward titration of propranolol should coincide with a downward titration in sedatives until a minimum level of sedative infusion is reached (propofol \<0.5mg/kg/h or midazolam \<1.0mg/h). Nurses will be instructed at each assessment to determine if sedative targets can be achieved with lower doses of sedatives. Daily upward titration of propranolol will be recommended if none of these conditions are met: (1)HR\<70 beats/min, (2) Mean Arterial Pressure \<70 mmHg or (3) norepinephrine or equivalent vasopressor dose increase to \>0.15 mcg/kg/min.
Study: NCT05096065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet - 120 mg - QD- Treatment A
Description: If the subject during Treatment A meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the First Treatment Cycle), in the Second Treatment Cycle, she will be assigned Treatment B - 80 mg (2 x 40 mg tablets) (QD), with food-intake restrictions.~If the subject during Treatment A fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the First Treatment Cycle), then she will be switched to the Second Treatment Cycle with Treatment D - 60 mg (BID) with food intake restrictions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet - 80 mg - QD - Treatment B
Description: If the subject on Treatment B meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment C - 60 mg (QD) with food-intake restrictions.~If the subject on Treatment B does not meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet - 60 mg - QD - Treatment C
Description: For up to 29 consecutive days with food-intake restrictions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet - 60 mg - BID - Treatment D
Description: If the subject on Treatment D fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), she will be discontinued from the study following completion of the Second Treatment Cycle.~If the subject during Treatment D meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of her Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet - 40 mg - BID - Treatment E
Description: For up to 29 consecutive days with food-intake restrictions
Study: NCT05626101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: Intravsical induction and maintenance BCG injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravsical induction and maintenance gemcitabin injections.
Study: NCT05590585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical emollient (moisturizer)
Description: Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
Study: NCT05548517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE)
Description: 9-hour eating window

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restriction
Description: daily calorie restriction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Description: daily calorie restriction
Study: NCT06408038

Intervention type: OTHER
Group type: OTHER
Intervention: For each patient included, the samples described below will be collected:
Description: * A single blood sample will be taken before initiation of the metastatic treatment line. The volume of total blood sampled is 34mL.~* A tumour sample (FFPE block already archived) from a metastasis (other than bone) if available or, failing this, from the primary breast tumour, will be sent to the sponsor in order to meet the objectives of the study.~Once the blood sample has been taken, patients will have completed their participation in the study.
Study: NCT05657028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: -In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
Study: NCT05705349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC/FTC/TAF
Description: Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to DOR/ISL
Description: Placebo tablet matched to DOR/ISL tablet taken by mouth.
Study: NCT04765007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness-based stress reduction
Description: Eight sessions of two hours and a half, one day per week during eight weeks. In addition, patients will perform a day of intensive silent practice of 6-8 hours of duration.~The content of each session balances three activities: the presentation of a topic, moments of dialogue and group exploration (using appreciative inquiry) and a Mindfulness practice.~The sessions will take place in online format, through the google meet application

Intervention type: OTHER
Group type: OTHER
Intervention: Minimal intervention
Description: A guided meditation program of eight weeks of duration will be provided to the patients and they will be informed about the procedure and the beneficial effects of the therapy.
Study: NCT05705349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BIC/FTC/TAF
Description: Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth.
Study: NCT06103162

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: flexible feeding plate
Description: One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
Study: NCT05592015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study: NCT04838314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional analgesia
Description: Peri operative regional analgesia by bilateral ESP catheter for 72h
Study: NCT05515848

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this retrospective study.
Study: NCT05360836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative treatment via telerehabilitation
Description: Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative treatment via telerehabilitation
Description: Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative treatmen + motor imagery
Description: Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, 5-minute massage, passive, active auxiliary normal range of motion. Ice application. Strengthening exercise after 4 weeks. The duration of treatment is 8 weeks. This group applies motor images for a maximum of 5 minutes. They will implement functionality-based motor images.
Study: NCT05440292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: For each stimulation day, low-frequency (1 Hz) ,1800 pulses(intensity of 100% resting motor threshold(RMT), duration 30 min) rTMS stimulation were delivered on the hotspot of unaffected hemisphere(Hotspot-rTMS Group) and the motor task activation poin of unaffected hemisphere(fMRI-rTMS Group). rTMS which guided by individualized navigation delivery 5 days a week for 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: For each stimulation day, low-frequency (1 Hz) ,1800 pulses(intensity of 100% resting motor threshold(RMT), duration 30 min) rTMS stimulation were delivered on the hotspot of unaffected hemisphere(Hotspot-rTMS Group) and the motor task activation poin of unaffected hemisphere(fMRI-rTMS Group). rTMS which guided by individualized navigation delivery 5 days a week for 4 weeks.
Study: NCT06103162

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: flexible feeding plate
Description: One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: flexible feeding plate
Description: One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
Study: NCT05551806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based self-help cognitive behavioural therapy
Description: The online CBT-I course will consist of an introductory module, followed by 6 weekly modules, incorporating the key CBT-I components, including sleep hygiene education, stimulus control, sleep restriction, relaxation training, and cognitive therapy.
Study: NCT05950568

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block typen II
Description: A 22 gauge needle was positioned between the quadratus lumborum muscle posterior border and the erector spinae muscle in the thoracolumbar fascia's middle layer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block III
Description: A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
Study: NCT05577975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Aspara @ smart grower
Description: The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention. The home-based program contains different horticultural, cognitive and multisensory stimulation activities such asking the PWD and the family caregiver to record the sense of touch and odor when taking care of the plant and the various changes of the plants by using the smart grower. Program evaluation will be conducted through focus groups with 15 participants with different levels of stress reduction after the intervention.
Study: NCT05934435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Empowered Relief
Description: psycho-educational pain skills training

Intervention type: OTHER
Group type: OTHER
Intervention: Empowered Relief
Description: psycho-educational pain skills training
Study: NCT04631939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metacognitive training game
Description: In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The intervention consists of 4 different puzzles. Unbeknownst to the player, the first pieces of evidence of each puzzle are often misleading, i.e. indicate the wrong solution, such that hasty decisions are punished. Players receive immediate feedback and are shown the correct response after submitting their solution, as well as explicit cues that educate them on the value of making adequately informed decisions. The order of the puzzles is fixed for each player, but different per session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control games
Description: In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The control intervention consists of 4 different puzzle games requiring exclusively dexterity and accuracy (i.e., not including any metacognitive elements). The order of the puzzles is fixed for each player, but different per session.
Study: NCT06423235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regular dose of JiRui® Prunella oral liquid
Description: Take 10ml twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2x regular dose of JiRui® Prunella oral liquid
Description: Take 20ml twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: regular dose of placebo
Description: Take 10ml twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2x regular dose of placebo
Description: Take 20ml twice a day
Study: NCT05669443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional PEEP
Description: Maintain positive end expiratory pressure at 5 cmH2O throughout the surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: optimized PEEP
Description: Immediately after induction of anesthesia, the patient remains unapplied to PEEP. After pneumoperitoneum + Trendelenburg posture, an appropriate PEEP value is derived using electrical impedance tomography (airtom®). And then derived value ( = optimized PEEP value) is applied until the end of the operation.
Study: NCT05054530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMA106 Injection
Description: GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GMA106 Matching Placebo
Description: Matching Placebo for GMA106
Study: NCT04630093

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Panel-based pharmacogenetic genotyping
Description: A DNA sample by saliva (via mouthwash swish and expectorate collection) or buccal cell (via buccal brush) will be obtained for pharmacogenetic testing and questionnaires will be administered at baseline and then again at 3 months and 6 months after receiving PGx results.
Study: NCT04528810

Intervention type: OTHER
Intervention: not applicable (Observational Study)
Description: This is an observational study and does not include interventions.